Drug
Spn 817
Spn 817: highest development phase Phase 2, developed by Supernus Pharmaceuticals. 3 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Supernus Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| SPN-817 NCT07141329 | Phase 2 | Focal Onset Seizures |
| SPN-817 NCT06798896 | Phase 2 | Focal Onset Seizures |
| SPN-817 NCT05518578 | Phase 2 | Epilepsy |
Latest
No recent events.
Follow Spn 817 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.